<DOC>
	<DOCNO>NCT01568320</DOCNO>
	<brief_summary>The Zenith® Dissection Clinical Trial clinical trial approve US FDA study safety effectiveness Zenith® Dissection Endovascular System treatment acute , complicate Type B aortic dissection .</brief_summary>
	<brief_title>Zenith® Dissection Clinical Trial</brief_title>
	<detailed_description />
	<criteria>1 . Age &lt; 18 year ; 2 . Other medical condition ( e.g. , cancer , congestive heart failure ) may cause patient noncompliant Clinical Investigation Plan , confound result , associate limited life expectancy ( i.e. , less 2 year ) ; 3 . Pregnant , breastfeeding , plan become pregnant within 60 month ; 4 . Unwilling unable comply followup schedule ; 5 . Inability refusal give informed consent ; 6 . Simultaneously participate another investigative device drug study . ( The patient must complete primary endpoint previous study least 30 day prior enrollment study . ) ; 7 . Additional medical restriction specify Clinical Investigation Plan ; 8 . Additional anatomical restriction specify Clinical Investigation Plan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aorta</keyword>
	<keyword>Thoracic</keyword>
	<keyword>Aortic dissection</keyword>
	<keyword>Rupture</keyword>
	<keyword>Type B</keyword>
	<keyword>DeBakey type III</keyword>
	<keyword>Endovascular</keyword>
</DOC>